Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Neurology

Comparative Efficacy and Safety of CGRP Monoclonal Antibodies and Oral Gepants for Migraine Prevention: Evidence from Randomized Controlled Trials and Network Meta-analysis (P10-15.014)

View Full Paper
Ask AI
Bookmark
Share

Authors

SASharath Chandra AnneSKShradha KakdeMKMeghnath Kakde

Discussion

Loading...

Member takes

Overview

Randomized trial compares the efficacy and safety of CGRP monoclonal antibodies and oral gepants for migraine prevention, indicating significant findings.

Key Points

  • This research aims to evaluate and compare the efficacy and safety of CGRP monoclonal antibodies and oral gepants for migraine prevention.
  • Used network meta-analysis to synthesize findings from multiple randomized controlled trials.
  • Analyzed SUCRA-based ranking to assess the effectiveness of interventions.
  • CGRP monoclonal antibodies showed higher efficacy for migraine prevention compared to oral gepants.
  • Safety profiles differed between the two treatments, with CGRP monoclonal antibodies having a better safety outcome.

Cite This Study

Anne et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f05665ehttps://doi.org/10.1212/wnl.0000000000216798
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CGRP Monoclonal Antibodies vs Gepants: Risk of Vascular Outcomes: A TriNetX Multicenter Electronic Medical Record Analysis (P10-15.012)2026
  2. 2BEYOND TRIPTANS: SYSTEMATIC REVIEW FOCUSING ON THE EFFICACY AND SAFETY PROFILE OF CGRP RECEPTOR ANTAGONISTS IN MIGRAINE MANAGEMENT2026
  3. 3Efficacy of CGRP Inhibitors in Preventive Pharmacotherapy for Migraine—A Network Meta-analysis and Systematic Review (P8-12.005)2024
  4. 4Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists2025
  5. 5Efficacy and safety of CGRP monoclonal antibodies in chronic migraine: a systematic review integrating randomized and real-world evidence2026